2020 ASCO Virtual Direct™ Highlights


 

ASCO 2020 Updates on IO in H&N Cancers: Cetuximab + Nivo, Cetuximab + Monalizumab, Pembro + ICOS Agonist: How Do They Affect Clinical Activities and Is ORR Improved?

17 views
September 18, 2020
Comments 0
Login to view comments. Click here to Login